CoChat
Sign Up
Cited by 13Treatment of Major DepressionNeurotransmitter Receptor Influence on BehaviorTryptophan and brain disorders

The DOI matches its Crossref record.

Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor*

Rosenzweig, Pierre, Patat, Alain, Zieleniuk, Isabelle, Cimarosti, Isabelle, Allain, Hervé, Gandon, Jean-Marc·1998·Clinical Pharmacology & Therapeutics
DOI 10.1016/s0009-9236(98)90155-2
Open this paper in CoChat — free account

Abstract

Background Patients with depression often have cognitive and psychomotor performance impairments. Antidepressive treatments can correct these deficits, provided sedative and anticholinergic adverse effects do not add to the preexisting condition, particularly in elderly patients. Newly developed antidepressants therefore should be without deleterious effects on cognitive functions, including memory. Befloxatone is a new antidepressant with a potent, selective, competitive, and reversible inhibitory activity on the A isoform of monoamine oxidase (MAO-A). Methods The effects on cognition and psychomotor performance of single oral doses of befloxatone (10 mg) and amitriptyline (50 mg) were compared in a randomized, double-blind, placebo-controlled, three-way crossover design trial in 12 healthy elderly (65 to 85 years) volunteers. The performances of the subjects were evaluated by a comprehensive battery of validated psychometric tests that explored alertness, psychomotor performance, information processing, and memory. Subjective feelings on mood and sleep were rated on visual analog scales. MAO-A inhibition was estimated by multiple titrations of 3,4-dihydrophenylglycol (DHPG) in plasma. Results Amitriptyline displayed the expected deleterious effects on performance tasks, critical flicker fusion threshold, digit symbol substitution, and body sway, and it deteriorated memory (immediate and delayed free recall of words). In contrast, befloxatone did not impair cognition or psyc…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0009-9236(98)90155-2

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Subject-rated alertness and behaviour upon waking was significantly poorer with amitriptyline (50mg) than placebo in healthy participants.

    “(Rosenzweig et al., 1998) found that subject-rated alertness and behaviour upon waking was significantly poorer with amitriptyline (50mg) than placebo.”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Rosenzweig et al., 1998

  • Amitriptyline, nortriptyline and particularly dothiepin have frequently been linked with poorer reports of daytime drowsiness.

    “At the same time, amitriptyline (Rosenzweig et al., 1998), nortriptyline (Hammack et al., 2002) and (particularly) dothiepin (Wilson et al., 2002) have frequently been linked with poorer reports of daytime drowsiness.”

    From Antidepressants and their effect on sleep (2005) · cites this paper as Rosenzweig et al., 1998

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 45

  1. Miller W. R., 1975, Psychol Bull, 82, 238, 10.1037/h0076367 · DOI
  2. Siegfried K. R., 1984, Drug Dev Res, 4, 533, 10.1002/ddr.430040508 · DOI
  3. Sternberg D. E., 1976, Arch Gen Psychiatry, 33, 219, 10.1001/archpsyc.1976.01770020055009 · DOI
  4. Coughlan A. K., 1984, Br J Psychiatry, 145, 164, 10.1192/bjp.145.2.164 · DOI
  5. Curran H. V., 1988, Psychopharmacology (Berl), 95, 520, 10.1007/BF00172967 · DOI
  6. Thompson P. J., 1982, Psychol Med, 12, 539, 10.1017/S003329170005563X · DOI
  7. Moskowitz H., 1986, Neuropsychobiology, 15, 38, 10.1159/000118285 · DOI · Paper page
  8. Deptula D., 1990, J Clin Psychopharmacol, 10, 105, 10.1097/00004714-199004000-00005 · DOI
  9. Raskin A., 1983, Psychopharmacol Bull, 19, 649
  10. Dechant K. L., 1991, Drugs, 41, 225, 10.2165/00003495-199141020-00007 · DOI
  11. Allain H., 1992, Psychopharmacology (Berl), 106, S56, 10.1007/BF02246237 · DOI
  12. Murdoch D., 1992, Drugs, 44, 604, 10.2165/00003495-199244040-00007 · DOI
  13. Spring B., 1992, Pychopharmacology (Berl), 108, 327, 10.1007/BF02245119 · DOI
  14. Wilde M. I., 1993, Drugs, 46, 895, 10.2165/00003495-199346050-00008 · DOI
  15. Lecrubier Y., 1994, Drug Saf, 10, 292, 10.2165/00002018-199410040-00003 · DOI
  16. Wesnes K. A., 1989, J Neural Transm, 28, 91
  17. Berlin I., 1990, Br J Clin Pharmacol, 30, 805, 10.1111/j.1365-2125.1990.tb05445.x · DOI
  18. Hindmarch I., 1992, Psychopharmacology (Berl), 106, S49, 10.1007/BF02246236 · DOI
  19. Kerr J. S., 1992, Hum Psychopharmacol, 7, 273, 10.1002/hup.470070407 · DOI
  20. Fairweather D. B., 1993, Int Clin Psychopharmacol, 8, 43, 10.1097/00004850-199300810-00007 · DOI
  21. Ramaekers J. G., 1994, Clin Neuropharmacol, 17, S9, 10.1097/00002826-199417001-00003 · DOI
  22. Koulu M., 1989, Br J Clin Pharmacol, 27, 243, 10.1111/j.1365-2125.1989.tb05357.x · DOI
  23. Scheinin M., 1990, Life Sci, 49, 75, 10.1016/0024-3205(91)90581-U · DOI
  24. Ansseau M., 1992, Clin Neuropharmacol, 15, 328B
  25. Patat A., 1996, J Clin Pharmacol, 36, 216, 10.1002/j.1552-4604.1996.tb04191.x · DOI
  26. Patat A., 1995, J Clin Pharmacol, 35, 633, 10.1002/j.1552-4604.1995.tb05022.x · DOI
  27. Luthringer R., 1996, Neuropsychobiology, 34, 98, 10.1159/000119299 · DOI
  28. Warot D., 1996, J Clin Pharmacol, 36, 942, 10.1002/j.1552-4604.1996.tb04762.x · DOI
  29. Hindmarch L., 1980, Br J Clin Pharmacol, 10, 189, 10.1111/j.1365-2125.1980.tb01745.x · DOI
  30. Allain H., 1993, Human psychopharmacology, measures and methods, vol IV, 143
  31. Seppala T., 1977, Acta Pharmacol Toxicol, 41, 472, 10.1111/j.1600-0773.1977.tb02158.x · DOI
  32. Linnoila M., 1984, Br J Clin Pharmacol, 18, 109S, 10.1111/j.1365-2125.1984.tb02589.x · DOI
  33. Rosvold H. E., 1956, J Consult Psychol, 20, 343, 10.1037/h0043220 · DOI · Paper page
  34. Hindmarch I., 1982, Pharmacopsychiatria, 15, 44, 10.1055/s-2007-1019549 · DOI
  35. McClelland G. R., 1989, Hum Psychopharmacol, 4, 3, 10.1002/hup.470040103 · DOI
  36. Kapteyn T. S., 1983, Agressologie, 24, 321
  37. Pavio A., 1969, J Exp Psychol, 80, 279, 10.1037/h0027273 · DOI
  38. Bond A. J., 1974, Br J Med Psychol, 47, 211, 10.1111/j.2044-8341.1974.tb02285.x · DOI · Paper page
  39. Parrott A. C., 1980, Psychopharmacology (Berl), 71, 173, 10.1007/BF00434408 · DOI
  40. Patat A., 1997, Hum Psychopharmacol, 12, 557, 10.1002/(SICI)1099-1077(199711/12)12:6<557::AID-HUP923>3.0.CO;2-P · DOI
  41. Patat A., 1995, Hum Psychopharmacol, 10, 111, 10.1002/hup.470100206 · DOI
  42. Ramaekers J. G., 1996, J Psychopharmacol, 10, 288, 10.1177/026988119601000405 · DOI
  43. Kerr J. S., 1993, Hum Psychopharmacol, 8, 107, 10.1002/hup.470080204 · DOI
  44. Anand H., 1990, Advances in Neurology; Alzheimer's disease, vol 51, 261
  45. van Veggel L., 1991, Biol Psychiatry, 29, 372S

Cited by

Sorted by citations

Metadata

Authors
Rosenzweig, P., Patat, A., Zieleniuk, I., Cimarosti, I., Allain, H., & Gandon, J.-M.
Affiliations
Biotrial (France) (FR)
Corresponding author
Rosenzweig, Pierre
Venue
Clinical Pharmacology & Therapeutics
Publisher
Wiley
Published
1998-08
Volume
64
Issue
2
Pages
211-222
ISSN
  • 0009-9236 (ISSN-L)
  • 1532-6535
DOI
10.1016/s0009-9236(98)90155-2
OpenAlex
W2140923325
Cited by
13
References
0
Citations by year
2018: 1 · 2013: 1 · 2012: 1
FWCI
0.21
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
monoamine oxidase A inhibitors, amitriptyline, cognitive performance, psychomotor performance, memory, elderly patients, antidepressant side effects, alertness, sleep, tricyclic antidepressants
MeSH terms
Aged, Aged, 80 and over, Amitriptyline, Antidepressive Agents, Tricyclic, Cognition, Depression, Double-Blind Method, Female, Humans, Male, Monoamine Oxidase Inhibitors, Oxazoles, Psychomotor Performance, Reference Values, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review